Denali Therapeutics Files 8-K
Ticker: DNLI · Form: 8-K · Filed: Jul 7, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Jul 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Denali Therapeutics filed a routine 8-K, no major news.
AI Summary
Denali Therapeutics Inc. filed an 8-K on July 7, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Denali Therapeutics Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for regulatory disclosure and does not contain any new material information that would indicate increased risk.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- July 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 46-3872213 (identification_number) — I.R.S. Employer Identification No.
- 161 Oyster Point Blvd. South San Francisco , California 94080 (address) — Address of principal executive offices
- ( 650 ) 866-8547 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Denali Therapeutics Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing details.
On what date was this 8-K filing reported as of?
The filing was made as of July 7, 2025, and the date of the earliest event reported is also July 7, 2025.
In which U.S. state is Denali Therapeutics Inc. incorporated?
Denali Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Denali Therapeutics Inc.?
The principal executive office address is 161 Oyster Point Blvd., South San Francisco, California 94080.
Does this filing indicate any specific new financial results or material events?
No, this filing primarily serves as a current report for regulatory disclosure and filing of exhibits, without detailing specific new financial results or material events beyond these categories.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 7, 2025 regarding Denali Therapeutics Inc. (DNLI).